WO2003057245A1 - Compositions servant a ameliorer le metabolisme lipidique - Google Patents
Compositions servant a ameliorer le metabolisme lipidique Download PDFInfo
- Publication number
- WO2003057245A1 WO2003057245A1 PCT/JP2002/013858 JP0213858W WO03057245A1 WO 2003057245 A1 WO2003057245 A1 WO 2003057245A1 JP 0213858 W JP0213858 W JP 0213858W WO 03057245 A1 WO03057245 A1 WO 03057245A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions
- lactoferrin
- lipid metabolism
- lactoferricin
- conalbumin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000037356 lipid metabolism Effects 0.000 title abstract 2
- 108010063045 Lactoferrin Proteins 0.000 abstract 3
- 102000010445 Lactoferrin Human genes 0.000 abstract 3
- 108010026206 Conalbumin Proteins 0.000 abstract 2
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 2
- 101800004361 Lactoferricin-B Proteins 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- CFFMZOZGXDAXHP-HOKBLYKWSA-N lactoferricin Chemical compound C([C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@H](C(=O)N1)[C@@H](C)O)=O)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CFFMZOZGXDAXHP-HOKBLYKWSA-N 0.000 abstract 2
- 239000004129 EU approved improving agent Substances 0.000 abstract 1
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract 1
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010020961 Hypocholesterolaemia Diseases 0.000 abstract 1
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract 1
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000001883 cholelithiasis Diseases 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 abstract 1
- 229940078795 lactoferrin Drugs 0.000 abstract 1
- 235000021242 lactoferrin Nutrition 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 230000037323 metabolic rate Effects 0.000 abstract 1
- 208000001022 morbid obesity Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02793463A EP1466621A4 (en) | 2001-12-28 | 2002-12-27 | COMPOSITIONS FOR ENHANCING LIPID METABOLISM |
| US10/500,245 US20050020484A1 (en) | 2001-12-28 | 2002-12-27 | Compositions for improving lipid metabolism |
| CA2471766A CA2471766C (en) | 2001-12-28 | 2002-12-27 | Compositions for improving lipid metabolism |
| AU2002359949A AU2002359949A1 (en) | 2001-12-28 | 2002-12-27 | Compositions for improving lipid metabolism |
| JP2003557602A JP3668241B2 (ja) | 2001-12-28 | 2002-12-27 | 脂質代謝改善用組成物 |
| US11/832,387 US20080014270A1 (en) | 2001-12-28 | 2007-08-01 | Methods for improved lipid metabolism and basal metabolic rate with lactoferrin |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001-400641 | 2001-12-28 | ||
| JP2001400641 | 2001-12-28 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/832,387 Division US20080014270A1 (en) | 2001-12-28 | 2007-08-01 | Methods for improved lipid metabolism and basal metabolic rate with lactoferrin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2003057245A1 true WO2003057245A1 (fr) | 2003-07-17 |
Family
ID=19189645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2002/013858 WO2003057245A1 (fr) | 2001-12-28 | 2002-12-27 | Compositions servant a ameliorer le metabolisme lipidique |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20050020484A1 (ja) |
| EP (2) | EP1466621A4 (ja) |
| JP (1) | JP3668241B2 (ja) |
| AU (1) | AU2002359949A1 (ja) |
| CA (1) | CA2471766C (ja) |
| WO (1) | WO2003057245A1 (ja) |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005112744A (ja) * | 2003-10-06 | 2005-04-28 | Nagase Iyakuhin Kk | ユビデカレノン錠 |
| JP2009221162A (ja) * | 2008-03-17 | 2009-10-01 | Yokohama Tlo Co Ltd | ラクトフェリンを有効成分とするｕｃｐ発現促進剤 |
| JP2010180219A (ja) * | 2010-03-04 | 2010-08-19 | Snow Brand Milk Prod Co Ltd | ラクトフェリン組成物 |
| JP2010229118A (ja) * | 2009-03-30 | 2010-10-14 | Up Well:Kk | リパーゼ阻害剤 |
| RU2446819C2 (ru) * | 2008-07-14 | 2012-04-10 | Макслак Байотекноледжи Корп. | Применение композиции для ингибирования образования жира тела и способ ингибирования образования жира тела |
| US10004747B2 (en) | 2010-05-05 | 2018-06-26 | Boehringer Ingelheim International Gmbh | Combination therapy |
| US10022379B2 (en) | 2008-04-03 | 2018-07-17 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
| US10023574B2 (en) | 2002-08-21 | 2018-07-17 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US10034877B2 (en) | 2008-08-06 | 2018-07-31 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
| US10092571B2 (en) | 2009-11-27 | 2018-10-09 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
| US10195203B2 (en) | 2012-05-14 | 2019-02-05 | Boehringr Ingelheim International GmbH | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| US10301313B2 (en) | 2006-05-04 | 2019-05-28 | Boehringer Ingelheim International Gmbh | Polymorphs |
| JP2021029208A (ja) * | 2019-08-28 | 2021-03-01 | 森永乳業株式会社 | アルコール代謝促進用組成物 |
| US11033552B2 (en) | 2006-05-04 | 2021-06-15 | Boehringer Ingelheim International Gmbh | DPP IV inhibitor formulations |
| US11291668B2 (en) | 2006-05-04 | 2022-04-05 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
| US11911387B2 (en) | 2010-11-15 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| US11911388B2 (en) | 2008-10-16 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1477182A4 (en) * | 2002-01-21 | 2009-05-27 | Nrl Pharma Inc | NEW ANALGETICS |
| TW200605902A (en) * | 2004-08-05 | 2006-02-16 | Maxluck Biotechnology Corp | Composition for lowering blood lipid |
| TW201002332A (en) | 2008-07-07 | 2010-01-16 | Univ Nat Chunghsing | Composition for preventing and controlling fatty liver disease |
| DE102009049702A1 (de) * | 2009-10-18 | 2011-04-21 | Vczs Venture Capital Zentralschweiz Ag | Verwendung von Lactoferrin und Lactoferrin enthaltende Zusammensetzungen |
| CN103327999B (zh) * | 2011-01-21 | 2016-08-10 | 狮王株式会社 | 促进脂肪分解组合物 |
| IT1404288B1 (it) * | 2011-01-25 | 2013-11-15 | Alphrema S R L | Composizioni ad uso topico per il trattamento delle adiposita' localizzate e dei relativi inestetismi |
| RU2537133C2 (ru) * | 2013-02-07 | 2014-12-27 | Закрытое акционерное общество "Инновационный научно-производственный центр "Пептоген" | ПРИМЕНЕНИЕ ТЕТРАПЕПТИДА Pro-Gly-Pro-Val В КАЧЕСТВЕ СРЕДСТВА ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ НАРУШЕНИЙ ЛИПИДНОГО ОБМЕНА, СПОСОБ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ НАРУШЕНИЙ ЛИПИДНОГО ОБМЕНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ НАРУШЕНИЙ ЛИПИДНОГО ОБМЕНА И СПОСОБ ЕЕ ПОЛУЧЕНИЯ |
| CN105744845A (zh) * | 2013-11-29 | 2016-07-06 | 雀巢产品技术援助有限公司 | 具有磷脂的营养组合物 |
| US20180160714A1 (en) * | 2016-12-12 | 2018-06-14 | Mead Johnson Nutrition Company | Nutritional compositions containing butyrate and uses thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991004015A1 (en) * | 1989-09-22 | 1991-04-04 | Bukh Meditec A/S | Controlled release composition |
| JPH05176713A (ja) * | 1990-09-20 | 1993-07-20 | Morinaga Milk Ind Co Ltd | 脂質代謝改善に有効な機能性食品 |
| WO1998044940A1 (en) * | 1997-04-10 | 1998-10-15 | Agennix, Inc. | Use of lactoferin in the treatment of allergen induced disorders |
| EP0955068A1 (en) * | 1998-05-04 | 1999-11-10 | Beta Pictoris Inc. | A case particularly for deodorants, insecticides, moth-repellant with a snap opening and closing mechanism |
| WO2000022909A2 (en) * | 1998-10-19 | 2000-04-27 | Biotech Australia Pty. Limited | Systems for oral delivery |
| JP2000198739A (ja) * | 1999-01-05 | 2000-07-18 | Tokiwa Yakuhin Kogyo Kk | チキン抽出物を含有する脂質代謝改善用ないしは肥満予防用または治療用の医薬組成物 |
| JP2000325046A (ja) * | 1999-05-19 | 2000-11-28 | Meiji Milk Prod Co Ltd | 肝炎を予防および治療する食品もしくは医薬品 |
| JP2001048808A (ja) * | 1999-08-09 | 2001-02-20 | Morinaga Milk Ind Co Ltd | 腸溶性糖衣錠 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6410212A (en) | 1987-07-03 | 1989-01-13 | Nippon Telegraph & Telephone | Electric absorption type optical modulator |
| DK0389795T3 (da) * | 1989-02-25 | 1993-08-02 | Morinaga Milk Industry Co Ltd | Bioaktive midler |
| SU1745174A1 (ru) * | 1989-07-20 | 1992-07-07 | Институт Региональных Проблем Питания Амн Ссср | "Печенье "Тамаша" |
| JP2960947B2 (ja) | 1989-12-25 | 1999-10-12 | 日清製粉株式会社 | 脂質分解酵素阻害剤 |
| JP2978581B2 (ja) | 1990-10-30 | 1999-11-15 | 日清製粉株式会社 | コレステロール抑制剤 |
| US5106836A (en) * | 1991-02-22 | 1992-04-21 | Clintec Nutrition Co. | Enteral diet |
| JP3009498B2 (ja) | 1991-03-28 | 2000-02-14 | 日清製粉株式会社 | 脂質分解酵素阻害剤 |
| CA2090658A1 (en) * | 1992-03-02 | 1993-09-03 | Kunio Ando | Formulated medicine for treatment and/or prevention of opportunistic infectious diseases complicated by infection with lentivirus |
| JPH0648955A (ja) * | 1992-07-29 | 1994-02-22 | Morinaga Milk Ind Co Ltd | 消化管細胞賦活化剤 |
| JP3497195B2 (ja) * | 1993-02-10 | 2004-02-16 | 森永乳業株式会社 | 変性低密度リポタンパク質結合剤 |
| JPH08217693A (ja) * | 1995-02-17 | 1996-08-27 | Yoshihisa Naito | 新規医薬組成物 |
| US6111081A (en) * | 1996-05-31 | 2000-08-29 | Baylor College Of Medicine | Lactoferrin variants and uses thereof |
| WO1998030235A1 (fr) * | 1997-01-09 | 1998-07-16 | Morinaga Milk Industry Co., Ltd. | Comprimes de lactoferrine |
| CN1195544C (zh) * | 1998-07-30 | 2005-04-06 | 森永乳业株式会社 | 用于慢性肝炎的肝功能改善剂 |
| JP2000197469A (ja) * | 1999-01-08 | 2000-07-18 | New Food Creation Gijutsu Kenkyu Kumiai | 血清脂質改善効果を有する機能性飲食品 |
| US6172040B1 (en) * | 1999-05-28 | 2001-01-09 | A. Satyanarayan Naidu | Immobilized lactoferrin antimicrobial agents and the use thereof |
| US20020119928A1 (en) * | 2000-10-27 | 2002-08-29 | Mcanalley Bill H. | Dietary supplement compositions |
| IT1317937B1 (it) * | 2000-11-17 | 2003-07-15 | Sigma Tau Healthscience Spa | Composizione per stimolare le difese immunitarie ed il metabolismo delferro comprendente una alcanoil l-carnitina e lattoferrina. |
| JP4592041B2 (ja) * | 2000-11-24 | 2010-12-01 | 株式会社Ｎｒｌファーマ | 生活の質を改善する新規食品の製造法および用途 |
| US20030040475A1 (en) * | 2001-01-16 | 2003-02-27 | Yasuhiro Toba | Agents for improving lipid metabolism and reducing high blood pressure |
-
2002
- 2002-12-27 AU AU2002359949A patent/AU2002359949A1/en not_active Abandoned
- 2002-12-27 EP EP02793463A patent/EP1466621A4/en not_active Withdrawn
- 2002-12-27 US US10/500,245 patent/US20050020484A1/en not_active Abandoned
- 2002-12-27 EP EP11174780A patent/EP2386311A1/en not_active Withdrawn
- 2002-12-27 CA CA2471766A patent/CA2471766C/en not_active Expired - Lifetime
- 2002-12-27 JP JP2003557602A patent/JP3668241B2/ja not_active Expired - Lifetime
- 2002-12-27 WO PCT/JP2002/013858 patent/WO2003057245A1/ja active Application Filing
-
2007
- 2007-08-01 US US11/832,387 patent/US20080014270A1/en not_active Abandoned
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991004015A1 (en) * | 1989-09-22 | 1991-04-04 | Bukh Meditec A/S | Controlled release composition |
| JPH05176713A (ja) * | 1990-09-20 | 1993-07-20 | Morinaga Milk Ind Co Ltd | 脂質代謝改善に有効な機能性食品 |
| WO1998044940A1 (en) * | 1997-04-10 | 1998-10-15 | Agennix, Inc. | Use of lactoferin in the treatment of allergen induced disorders |
| EP0955068A1 (en) * | 1998-05-04 | 1999-11-10 | Beta Pictoris Inc. | A case particularly for deodorants, insecticides, moth-repellant with a snap opening and closing mechanism |
| WO2000022909A2 (en) * | 1998-10-19 | 2000-04-27 | Biotech Australia Pty. Limited | Systems for oral delivery |
| JP2000198739A (ja) * | 1999-01-05 | 2000-07-18 | Tokiwa Yakuhin Kogyo Kk | チキン抽出物を含有する脂質代謝改善用ないしは肥満予防用または治療用の医薬組成物 |
| JP2000325046A (ja) * | 1999-05-19 | 2000-11-28 | Meiji Milk Prod Co Ltd | 肝炎を予防および治療する食品もしくは医薬品 |
| JP2001048808A (ja) * | 1999-08-09 | 2001-02-20 | Morinaga Milk Ind Co Ltd | 腸溶性糖衣錠 |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP1466621A4 * |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10202383B2 (en) | 2002-08-21 | 2019-02-12 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US10023574B2 (en) | 2002-08-21 | 2018-07-17 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| JP4601934B2 (ja) * | 2003-10-06 | 2010-12-22 | ナガセ医薬品株式会社 | ユビデカレノン錠 |
| JP2005112744A (ja) * | 2003-10-06 | 2005-04-28 | Nagase Iyakuhin Kk | ユビデカレノン錠 |
| US11919903B2 (en) | 2006-05-04 | 2024-03-05 | Boehringer Ingelheim International Gmbh | Polymorphs |
| US11291668B2 (en) | 2006-05-04 | 2022-04-05 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
| US11084819B2 (en) | 2006-05-04 | 2021-08-10 | Boehringer Ingelheim International Gmbh | Polymorphs |
| US11033552B2 (en) | 2006-05-04 | 2021-06-15 | Boehringer Ingelheim International Gmbh | DPP IV inhibitor formulations |
| US10301313B2 (en) | 2006-05-04 | 2019-05-28 | Boehringer Ingelheim International Gmbh | Polymorphs |
| JP2009221162A (ja) * | 2008-03-17 | 2009-10-01 | Yokohama Tlo Co Ltd | ラクトフェリンを有効成分とするｕｃｐ発現促進剤 |
| US10022379B2 (en) | 2008-04-03 | 2018-07-17 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
| US10973827B2 (en) | 2008-04-03 | 2021-04-13 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
| RU2446819C2 (ru) * | 2008-07-14 | 2012-04-10 | Макслак Байотекноледжи Корп. | Применение композиции для ингибирования образования жира тела и способ ингибирования образования жира тела |
| US10034877B2 (en) | 2008-08-06 | 2018-07-31 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
| US11911388B2 (en) | 2008-10-16 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
| JP2010229118A (ja) * | 2009-03-30 | 2010-10-14 | Up Well:Kk | リパーゼ阻害剤 |
| US10092571B2 (en) | 2009-11-27 | 2018-10-09 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
| JP2010180219A (ja) * | 2010-03-04 | 2010-08-19 | Snow Brand Milk Prod Co Ltd | ラクトフェリン組成物 |
| US10004747B2 (en) | 2010-05-05 | 2018-06-26 | Boehringer Ingelheim International Gmbh | Combination therapy |
| US11911387B2 (en) | 2010-11-15 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| US10195203B2 (en) | 2012-05-14 | 2019-02-05 | Boehringr Ingelheim International GmbH | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| JP2021029208A (ja) * | 2019-08-28 | 2021-03-01 | 森永乳業株式会社 | アルコール代謝促進用組成物 |
| JP7369568B2 (ja) | 2019-08-28 | 2023-10-26 | 森永乳業株式会社 | アルコール代謝促進用組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20080014270A1 (en) | 2008-01-17 |
| US20050020484A1 (en) | 2005-01-27 |
| EP1466621A4 (en) | 2009-05-27 |
| JP3668241B2 (ja) | 2005-07-06 |
| EP2386311A1 (en) | 2011-11-16 |
| CA2471766A1 (en) | 2003-07-17 |
| CA2471766C (en) | 2011-01-11 |
| AU2002359949A1 (en) | 2003-07-24 |
| JPWO2003057245A1 (ja) | 2005-05-12 |
| EP1466621A1 (en) | 2004-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2003057245A1 (fr) | Compositions servant a ameliorer le metabolisme lipidique | |
| EP1520582A3 (en) | Use of dipeptidylpetidase inhibitors to regulate glucose metabolism | |
| MXPA05009933A (es) | Composiciones que comprenden acidos grasos y aminoacidos. | |
| WO2002080860A3 (en) | Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism | |
| Tipton | Nutrition for acute exercise-induced injuries | |
| WO2002028379A3 (en) | Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases | |
| DE60127457D1 (de) | Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen | |
| WO1999066917A3 (en) | Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid | |
| WO2002068650A3 (en) | Modified and stabilized gdf propeptides and uses thereof | |
| WO2001090091A8 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| EP2275140A3 (en) | Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities | |
| WO2003007888A3 (en) | Fat accumulation-modulating compounds | |
| WO2004016101A3 (en) | Compositions comprising dietary fat complexer and methods for their use | |
| WO2005046580A3 (en) | Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism | |
| CA2613792A1 (en) | Methods and compositions for the prevention and treatment of inflammatory disease | |
| WO2007025988A3 (en) | Liquid formulations of pegylated growth hormone | |
| WO2002024883A3 (en) | Lactic acid bacteria capable of reducing an individual's tendency to develop allergic reactions | |
| WO2004111084A3 (en) | Peptides enhancing ceh activity or inhibiting acat activity, pharmaceutical compositions comprising these peptides and their use in the treatment of atherosclerosis | |
| WO2011031063A3 (ko) | 항 4-1bb 항체를 포함하는 대사성 질환의 예방 또는 치료용 조성물 | |
| PL1959746T3 (pl) | Ulepszona kompozycja tłuszczowa | |
| WO2000043036A3 (en) | Lipoprotein complexes and compositions containing them | |
| AU2002344841A1 (en) | Truncated apolipoprotein b-containing lipoprotein particles for delivery of components to tissues or cells | |
| Scognamiglio et al. | Current drugs and nutraceuticals for the treatment of patients with dyslipidemias | |
| MX2021002902A (es) | Composicion farmaceutica para prevenir o tratar la enfermedad del higado graso no alcoholico, que contiene ligando gpr119 como principio activo. | |
| WO2007101066A3 (en) | Methods and compositions for improving cardiovascular risk factors and metabolic risk factors that cause syndrome x |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2003557602 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2471766 Country of ref document: CA Ref document number: 10500245 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002793463 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2002793463 Country of ref document: EP |